M. Kudrimoti

Patient‐reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy

A. Garden, R. Tishler, L. Elting, 2008, Cancer.

Dusquetide: A novel innate defense regulator demonstrating a significant and consistent reduction in the duration of oral mucositis in preclinical data and a randomized, placebo-controlled phase 2a clinical study.

Oreola Donini, O. Donini, S. Sonis, 2016, Journal of biotechnology.

Radiotherapy in Managing Metastatic Hepatocellular Carcinoma With Cardiac Involvement and Pulmonary Tumor Thromboemboli: A Case Report

Zhonglin Hao, M. Kudrimoti, E. Amoah, 2023, Cureus.

Dusquetide: Reduction in oral mucositis associated with enduring ancillary benefits in tumor resolution and decreased mortality in head and neck cancer patients

O. Donini, S. Sonis, F. Worden, 2017, Biotechnology reports.

Synopsis of Supraclavicular Sarcoma: Synthesis of Stratagem and Solutions

Jeremiah A. Johnson, A. Kaushal, M. Kudrimoti, 2022, International Journal of Radiation Oncology, Biology, Physics.